Decoy Therapeutics Inc.
Moat Score — Decoy Therapeutics Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | The IMP3ACT AI/ML peptide-engineering platform and associated pipeline IP (including the acquired SP-3164 molecule) represent the company's core asset, but as preclinical technology it is unproven and not yet protected by any approved product or validated commercial advantage. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue, going-concern-flagged preclinical company with no manufacturing or commercial infrastructure, Decoy has no realized cost advantage over any competitor. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products and no sales, Decoy has no ability to set prices in any market today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in peptide drug discovery or in Decoy's current business activities. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no commercial customers or prescribers yet, there is no switching-cost dynamic protecting the company's position. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Non-dilutive grant backing from the Gates Foundation and BARDA gives Decoy a modest funding advantage over unsponsored preclinical peers targeting the same underserved immunocompromised-patient niche, but this is a thin edge given the company's tiny scale and going-concern risk. |